IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Keith D. ALLEN

Serial No.: 09/903,396
Filed: July 10, 2001

Docket No.: R-359
Group Art Unit: 1632
Examiner: Unassigned

For: Transgenic Mice Containing Glucocorticoid-
Induced Receptor Gene Disruptions

RESPONSE TO NOTICE TO COMPLY WITH NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURE REQUIREMENTS

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply mailed April 22, 2002, regarding the above-captioned application, Applicants submit herewith:

1. A sequence listing on paper and in computer readable form pursuant to 37 C.F.R. §1.821(c) and (e); and

2. A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.

The content of the paper and computer readable copies of the sequence listing submitted in this application are the same. Moreover, as the sequence listing merely presents nucleotide and/or amino acid sequences that appeared in the application as originally filed in accordance with 37 C.F.R. §1.821-1.825, no new matter has been introduced into the application.

Accordingly, Applicants respectfully request the entry of the paper and computer readable forms of the sequence listing into the application.

Date: June 20, 2002

Respectfully submitted,

ROBERT J. DRISCOLL, Reg. 4 7,536
for JANE K. BABIN, Reg. 47.22 1

Deltagen, Inc.
740 Bay Road
Redwood City, CA 94063
(650) 569-5100

I certify that this amendment and enclosures are being deposited with the U. S. Postal Service with sufficient postage as first class mail in an envelope addressed to U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202, on June 20, 2002.

Gayle D. Peterson

R-359

UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/903,396	07/10/2001	Keith D. Allen	R-359

DeltaGen, Inc.
740 Bay Road
Redwood City, CA 94063

CONFIRMATION NO. 9463
FORMALITIES LETTER

OC000000007918939

Date Mailed: 04/22/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- **For Rules Interpretation, call (703) 308-4216**
- **To Purchase PatentIn Software, call (703) 306-2600**
- **For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov**

A copy of this notice MUST be returned with the reply.

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE